Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue (2016 - 2018)

Neurocrine Biosciences' Current Deferred Revenue history spans 9 years, with the latest figure at $731000.0 for Q1 2018.

  • For Q1 2018, Current Deferred Revenue fell 79.42% year-over-year to $731000.0; the TTM value through Mar 2018 reached $731000.0, down 79.42%, while the annual FY2017 figure was $731000.0, 55.53% up from the prior year.
  • Current Deferred Revenue reached $731000.0 in Q1 2018 per NBIX's latest filing, roughly flat from $731000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $10.2 million in Q1 2015 to a low of $52000.0 in Q2 2014.
  • Average Current Deferred Revenue over 5 years is $2.7 million, with a median of $731000.0 recorded in 2017.
  • Peak YoY movement for Current Deferred Revenue: tumbled 98.36% in 2014, then soared 1663.96% in 2016.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2014, then surged by 206.86% to $10.2 million in 2015, then crashed by 95.39% to $470000.0 in 2016, then surged by 55.53% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
  • Per Business Quant, the three most recent readings for NBIX's Current Deferred Revenue are $731000.0 (Q1 2018), $731000.0 (Q4 2017), and $3.6 million (Q1 2017).